Where Do You Envision The Biopharmaceutical Industry In 2032 And Why?

IN THE NEXT DECADE, I ENVISION THE BIOPHARMA INDUSTRY WILL BECOME MORE FOCUSED ON HOLISTIC CARE OF CHRONIC DISEASES. Holistic care is defined as (i) disease intervention, (ii) side effect management, (iii) supportive care, (iv) combination therapy, and/or (v) adjunct treatment through repurposing of older approved drugs. Narrowly focused disease modifying treatments often are not able to achieve their optimal patient value because of the need for drug holiday, subtherapeutic dosing, or patient noncompliance due to intolerable and neglected side effects. Total patient management, including the importance of patient comfort and dignity, will provide better patient outcomes, reduce cost of chronic disease management, and enhance patients’ comfort and participation in their treatment journey, as well as potentially lifetime productivity.

LISA CONTE is the founder, president, and CEO of Jaguar Health, a plant-based prescription pharma company focused on new ways of treating and curing gastro-intestinal and mental health disorders.